Abstract # 2236 A Phase II Trial of Trilogy-based Prostate SBRT: Initial Report of Favorable Acute Toxicity Outcomes

Presenter: Fernandez, Eduardo

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

Prostate SBRT utilizing Varian Trilogy offers high radiobiologic dose therapy with favorable acute urinary and rectal toxicity. Further follow-up will be needed to confirm these early toxicity results and provide meaningful disease control outcomes. This protocol is currently open and continues to accrue patients.